AEterna Zentaris Inc. (NASDAQ: AEZS) announced that the FDA has granted Fast Track designation for the Company's PI3K/Akt pathway inhibitor ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE